Synjardy and Visual impairment - a phase IV clinical study of FDA data

Summary:

Visual impairment is reported as a side effect among people who take Synjardy (empagliflozin; metformin hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Trulicity, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Visual impairment when taking Synjardy. It is created by eHealthMe based on reports of 2,896 people who have side effects when taking Synjardy from the FDA, and is updated regularly.

What is Synjardy?

Synjardy has active ingredients of empagliflozin; metformin hydrochloride. eHealthMe is studying from 2,928 Synjardy users. Check the latest studies of Synjardy.

What is Visual impairment?

Visual impairment is found to be associated with 2,250 drugs and 2,336 conditions by eHealthMe. Check the latest studies of Visual impairment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

2,896 people reported to have side effects when taking Synjardy.
Among them, 25 people (0.86%) have Visual impairment.

Among these 25 people:

How long have people been on Synjardy when they have Visual impairment? *

What is the gender of people who have Visual impairment when taking Synjardy? *

female: 56 %
male: 44 %

What is the age of people who have Visual impairment when taking Synjardy? *

What are other drugs people take besides Synjardy? *

What are other side effects people have besides Visual impairment? *

Dizziness: 6 people, 24.00%
Fatigue (feeling of tiredness): 5 people, 20.00%
Weight Increased: 4 people, 16.00%
Nausea And Vomiting: 4 people, 16.00%
Blood Glucose Increased: 4 people, 16.00%
Diabetes: 3 people, 12.00%
Weight Decreased: 3 people, 12.00%
Impulsive Behavior: 3 people, 12.00%
Menstrual Disorder (disease of menstrual cycle): 3 people, 12.00%
Nausea (feeling of having an urge to vomit): 3 people, 12.00%

What are the existing conditions these people have? *

Type 2 Diabetes: 12 people, 48.00%
Schizoaffective Disorder Bipolar Type (mental illness featuring schizophrenia and a mood disorder with mania): 3 people, 12.00%
Diabetes: 3 people, 12.00%
Urination - Excessive Volume: 2 people, 8.00%
Stress And Anxiety: 1 person, 4.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.00%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 4.00%
Hiv Infection: 1 person, 4.00%
High Blood Pressure: 1 person, 4.00%
Cardiac Disorder: 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Synjardy and have Visual impairment?

- Check whether Visual impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Synjardy:

Synjardy (2,928 reports)

Visual impairment treatments and more:

Visual impairment (128,338 reports)

How severe was Visual impairment and when was it recovered:

Visual impairment in Synjardy

Expand to all the drugs that have ingredients of empagliflozin; metformin hydrochloride:

Visual impairment and drugs with ingredients of empagliflozin; metformin hydrochloride (16 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Synjardy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual impairment:

Visual impairment (2,250 drugs)

Browse all the conditions that are associated with Visual impairment:

Visual impairment (2,336 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on empagliflozin; metformin hydrochloride (the active ingredients of Synjardy) and Synjardy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.